Aram Chung,
Professor, School of Biomedical Engineering,
Korea University
Aram Chung obtained his B.S. in Mechanical Engineering from Seoul National University (SNU) in 2006, followed by a Ph.D. in Mechanical Engineering from Cornell University in 2011. From 2011 to 2013, he conducted postdoctoral studies in Bioengineering at the University of California, Los Angeles (UCLA). He then assumed the role of Assistant Professor in the Mechanical Engineering Department at Rensselaer Polytechnic Institute (RPI). In 2017, Dr. Chung moved to the School of Biomedical Engineering at Korea University, where he currently serves as a Professor.
His research pioneered the establishment of microfluidic platforms for immunotherapy, genome editing, and cellular engineering. Additionally, he has taken on a leadership role in technology entrepreneurship, co-founding a company (MxT Biotech) that commercializes intellectual property developed in his lab.
Microfluidic Platforms for Immunotherapy and Genome Editing
Thursday, 7 November 2024 at 11:00
Add to Calendar ▼2024-11-07 11:00:002024-11-07 12:00:00Europe/LondonMicrofluidic Platforms for Immunotherapy and Genome EditingLab-on-a-Chip, Microfluidics, and Organ-on-a-Chip Asia 2024 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
The internalization of biomolecules in cells, such as DNAs, RNAs, plasmid DNAs, proteins, and CRISPR systems, is an indispensable process for studies ranging from basic biology to clinical applications. Tools such as viral vectors, cationic lipids, and electroporators have traditionally been used to deliver external biomolecules into cells; however, they are suboptimal for achieving high levels of delivery while preserving cell viability, phenotype, and function.
To address these challenges, our research group is focusing on developing next-generation microfluidics-based intracellular delivery platforms. By leveraging intrinsic fluid-cell interactions within confined microchannels, we create transient discontinuities on the cell membrane, internalizing external biomolecules into the cells. Using this principle, we have successfully demonstrated highly effective biomolecule delivery into various cells, including human primary stem and immune cells with high cell stability. In this talk, I will discuss our recent microfluidic intracellular delivery platform developments and their promising applications in genome editing and cancer immunotherapy.
Add to Calendar ▼2024-11-07 00:00:002024-11-08 00:00:00Europe/LondonLab-on-a-Chip, Microfluidics, and Organ-on-a-Chip Asia 2024Lab-on-a-Chip, Microfluidics, and Organ-on-a-Chip Asia 2024 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2024-11-07 11:00:002024-11-07 12:00:00Europe/LondonMicrofluidic Platforms for Immunotherapy and Genome EditingLab-on-a-Chip, Microfluidics, and Organ-on-a-Chip Asia 2024 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
